Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
101 hedge funds and large institutions have $734M invested in Revance Therapeutics, Inc. in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 20 closing their positions.
103% more call options, than puts
Call options by funds: $944K | Put options by funds: $466K
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 110 → 101 (-9)
14% less capital invested
Capital invested by funds: $854M → $734M (-$120M)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$9.39M |
| 2 |
Renaissance Technologies
New York
|
+$8.71M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.52M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.23M |
| 5 |
JP Morgan Chase
New York
|
+$3.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.8M |
| 2 |
Millennium Management
New York
|
-$5.27M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.32M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.17M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.08M |
RVNC Hedge Fund Activity: Q4 2018 in Review
101 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2018, worth a combined $734M — down 14% from $854M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of RVNC and 12 opened new positions — a net loss of 8 holders — while 30 trimmed existing stakes and 34 added.
The largest buyer was Franklin Resources, adding an estimated $9.39M. The largest seller was Fidelity Investments, cutting an estimated $5.8M.
- 101 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2018, down from 110 in Q3 2018.
- Funds reported $734M of Revance Therapeutics, Inc. stock for Q4 2018, down 14% quarter-over-quarter.
- 12 funds opened new Revance Therapeutics, Inc. positions in Q4 2018 and 20 closed out, a net change of -8 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2018 was Franklin Resources, an estimated $9.39M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2018 was Fidelity Investments, an estimated $5.8M sold.
Based on aggregated 13F filings for Q4 2018.